欢迎访问qy千亿官网官方网站

图片名

全国订购热线:
18966759382

首页 > 定制合成 > 其他产品

其他产品
小分子PEG 嵌段共聚物 纳米材料 糖化学 荧光量子点 其他产品

CAS:1189966-73-1|Ganciclovir-d5,BW 759-d5; 2'-Nor-2'-deoxyguanosine-d5

作者:QY千亿国际 发布时间:2025-05-29 09:47:03 次浏览

生物活性:Ganciclovir-d5 is the deuterium labeled Ganciclovir. Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1)[1][2][3].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
QY千亿国际 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量:260.26
Formula:C9H8D5N5O4
CAS 号:1189966-73-1
非标记 CAS:82410-32-0
性状:固体
颜色:White to off-white
中文名称:更昔洛韦 d5
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Powder:-20°C:3 years
In solvent:-80°C:6 months,-20°C:1 month
纯度 & 产品资料
纯度: 98.32%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638.
 [Content Brief]
[3]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.
 [Content Brief]
[4]. Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115.
 [Content Brief]
[5]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12.
 [Content Brief]
[6]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4.
 [Content Brief]
[7]. Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197.
 [Content Brief]